Abbott announced that the European Commission (EC) has approved Humira (adalimumab) for the treatment of adults with severe axial spondyloarthritis (axSpA) who have no X-ray evidence of structural damage.

Abbott announced that the European Committee for Medicinal Products for Human Use ( CHMP ) has issued a positive opinion for  Humira ( adalimumab ) in adults with moderate to severely active ulcerative colitis ( UC ) who have not responded to, cannot tolerate or have medical contraindications to conventional therapies.